BPC-157 vs Icotrokinra
Overview
BPC-157 is primarily a healing & recovery peptide, while Icotrokinra is used for immune support.
This page compares BPC-157 and Icotrokinra across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| BPC-157 | Icotrokinra | |
|---|---|---|
| Category | Healing & Recovery | Immune Support |
| Regulatory status (US) | Compounding (Rx) — Apr 2026 | FDA approved |
| Typical dosage | 250-500 mcg | — |
| Frequency | daily | — |
| Reported benefits | Accelerated wound healing, tendon and ligament repair, gut health improvement, reduced inflammation, neuroprotective effects | — |
| Reported side effects | Generally well-tolerated. Rare: injection site reactions, mild fatigue | — |
Key differences
Primary use. BPC-157 is categorised under Healing & Recovery, while Icotrokinra falls under Immune Support. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. BPC-157: not FDA-approved; compounding permitted with a prescription as of April 2026. Icotrokinra: FDA-approved.
Dosing. BPC-157 is typically dosed at 250-500 mcg (daily). Typical dosing for Icotrokinra is not catalogued.
Can you stack them?
Some protocols combine peptides, but stacking BPC-157 and Icotrokinra has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between BPC-157 and Icotrokinra?
- BPC-157 is primarily a healing & recovery peptide, while Icotrokinra is used for immune support. BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Icotrokinra is FDA-approved for one or more indications.
- What is BPC-157 used for?
- Healing & recovery, gut health.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- Can you take BPC-157 and Icotrokinra together?
- Some users combine peptides within a single protocol, but stacking BPC-157 and Icotrokinra has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is BPC-157 or Icotrokinra FDA-approved?
- BPC-157 is not FDA-approved; compounding permitted with a prescription (as of April 2026). Icotrokinra is FDA-approved for one or more indications.
Read the full articles
- BPC-157 — full monograph: mechanism, research, dosing & references
- Icotrokinra — full monograph: mechanism, research, dosing & references